```
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:26:28 ON 29 JAN 2011

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                           SINCE FILE      TOTAL
                                                 ENTRY        SESSION
FULL ESTIMATED COST                               0.23          0.23

FILE 'BIOSIS' ENTERED AT 14:27:16 ON 29 JAN 2011
Copyright (c) 2011 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:27:16 ON 29 JAN 2011

FILE 'CAPLUS' ENTERED AT 14:27:16 ON 29 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:27:16 ON 29 JAN 2011
COPYRIGHT (C) 2011 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 14:27:16 ON 29 JAN 2011
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s label? (4a) target and linker (4a) peptide bonds
L1             9 LABEL? (4A) TARGET AND LINKER (4A) PEPTIDE BONDS

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2             8 DUP REM L1 (1 DUPLICATE REMOVED)

=> d l2 bib abs 1-8

L2   ANSWER 1 OF 8  USPATFULL on STN
AN      2010:363838  USPATFULL
TI      Multi-oligomeric or multi--polymeric compositions comprising labeled
        moieties and binding partners
IN      Rabbani, Elazar, New York, NY, UNITED STATES
        Stavrianopoulos, Jannis G., Bayshore, NY, UNITED STATES
        Donegan, James J., Long Beach, NY, UNITED STATES
PA      ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC., NEW YORK, NY, UNITED
        STATES (U.S. corporation)
PI      US 20100324268      A1  20101223
AI      US 2010-803355      A1  20100624 (12)
RLI     Division of Ser. No. US 2009-399393, filed on 6 Mar 2009, PENDING
        Division of Ser. No. US 2003-407818, filed on 3 Apr 2003, Pat. No. US
        7514551
DT      Utility
FS      APPLICATION
LREP    ENZO BIOCHEM, INC., 527 MADISON AVENUE (9TH FLOOR), NEW YORK, NY, 10022,
        US
CLMN    Number of Claims: 40
ECL     Exemplary Claim: 1-98
DRWN    1 Drawing Page(s)
LN.CNT 1182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention provides multisignal labeling reagents and these
        are useful in a number of biochemical applications, including the
```

manufacture of biomolecular probes and their use in detecting or
amplifying analyte-specific moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 2 OF 8   USPATFULL on STN
AN   2009:288160   USPATFULL
TI   Multisignal Labeling Reagents, and Processes and Uses Therefor
IN   Rabbani, Elazar, New York, NY, UNITED STATES
      Stavrianopoulos, Jannis G., Bayshore, NY, UNITED STATES
      Donegan, James J., Long Beach, NY, UNITED STATES
PI   US 20090258374   A1 20091015
AI   US 2009-399393   A1 20090306 (12)
RLI   Division of Ser. No. US 2003-407818, filed on 3 Apr 2003, Pat. No. US
      7514551
DT   Utility
FS   APPLICATION
LREP THE WEBB LAW FIRM, P.C., 700 KOPPERS BUILDING, 436 SEVENTH AVENUE,
      PITTSBURGH, PA, 15219, US
CLMN Number of Claims: 88
ECL   Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention provides multisignal labeling reagents and these
      are useful in a number of biochemical applications, including the
      manufacture of biomolecular probes and their use in detecting or
      amplifying analyte-specific moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 3 OF 8 WPIDS COPYRIGHT 2011   THOMSON REUTERS on STN DUPLICATE
      1
AN   2004-727850 [200471]   WPIDS
CR   2009-P86761; 2010-Q65033
TI   Composition of multi signal labeling reagents, useful for detecting or
      quantifying analyte in specimen, has oligomer/polymer having labeled
      moieties, reactive groups and charged groups linked to oligomer/polymer
DC   B04; D16
IN   DONEGAN J J; RABBANI E; STAVRIANOPOULOS J G
PA   (DONE-I) DONEGAN J J; (ENZO-N) ENZO LIFE SCI INC; (RABB-I) RABBANI E;
      (STAV-I) STAVRIANOPOULOS J G
CYC   36
PIA   US 20040198971 A1 20041007 (200471)* EN 20[1]
      CA 2461445   A1 20041003 (200471) EN
      JP 2004309486   A 20041104 (200472) JA 29
      EP 1489422   A2 20041222 (200501) EN
      JP 2008148709   A 20080703 (200845) JA 22
      US 7514551   B2 20090407 (200925) EN
      JP 4434819   B2 20100317 (201020) JA 26
      EP 1489422   A3 20100908 (201059) EN
ADT   US 20040198971 A1 US 2003-407818 20030403; US 7514551 B2 US 2003-407818
      20030403; CA 2461445 A1 CA 2004-2461445 20040319; JP 2004309486 A JP
      2004-110340 20040402; JP 2008148709 A Div Ex JP 2004-110340 20040402; JP
      4434819 B2 JP 2004-110340 20040402; EP 1489422 A2 EP 2004-8226 20040405;
      JP 2008148709 A JP 2008-5049 20080111; EP 1489422 A3 EP 2004-8226 20040405
FDT   JP 4434819 B2 Previous Publ JP 2004309486 A
PRAI US 2003-407818   20030403
AN   2004-727850 [200471]   WPIDS
CR   2009-P86761; 2010-Q65033
AB   US 20040198971 A1   UPAB: 20050707

NOVELTY – A composition (I) of matter comprising an oligomer or polymer having two or more labeled groups, where the label or labels are chemically linked to the oligomer or polymer, one or more reactive groups, and one or more charged groups where the charged groups are covalently linked to the oligomer or polymer or comprise part of the backbone of the oligomer or polymer, or any of their combination, is new.

DETAILED DESCRIPTION – A composition (I) of matter comprises

(a) an oligomer or polymer comprising two or more labeled moieties, where the label or labels are chemically linked to the oligomer or polymer, one or more reactive groups, and one or more charged groups where the charged groups are covalently linked to the oligomer or polymer or comprise part of the backbone of the oligomer or polymer, or any of their combination;

(b) a nucleic acid strand or a complex of two or more nucleic acid strands, where the strand or complex comprises one or more reactive groups and two or more labeled nucleotides or labeled nucleotide analogs;

(c) a nucleic acid strand or a complex of two or more nucleic acid strands, where the strand or complex comprises two or more labeled nucleotides or labeled nucleotide analogs, and one or more binding partners different from the labels;

(d) a compound having the formula (F1); or

(e) a compound having the formula (F2).

In formula (F1),

Q = a non-inherent charged group;

n = 1 or greater;

D = label;

m = 2 or greater;

R = one or more reactive group;and

P = oligomer or polymer.

In formula (F2),

D = label;

m = 2 or greater;

R = one or more reactive group;and

P = synthetic or chimeric oligomer or polymer, D or one or more of monomeric units of P has one or more charged groups.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition (II) comprising a target molecule that has been labeled using (I); and

(2) a composition (III) prepared by a target labeling process comprising (i) providing a target for labeling, and a labeling reagent having the formula (F1) or (F2), (ii) reacting the target and the labeling reagent to form the composition having the formula (F3) or (F4).

L = linkage or linker between the oligomer or polymer and the target.

USE – (Ic) is useful for labeling a target molecule, which involves attaching or binding (Ic), to the target molecule chosen from peptides, proteins, antibodies, enzymes, enzyme substrates, ligands, hormones, receptors, antigens, haptens, lectins, avidin, streptavidin, toxins, carbohydrates, oligosaccharides, polysaccharides, ribonucleotides, deoxyribonucleotides, dideoxyribonucleotides, analogs of deoxynucleotides, ribonucleotides and dideoxynucleotides, modified deoxynucleotides, modified ribonucleotides, modified dideoxynucleotides, oligonucleotides and polynucleotides. (Ic) is useful for detecting or quantifying an analyte in a specimen, which involves:

(a) providing a specimen where an analyte is sought to be detected or quantified, (Ic) comprising a first non-hybridizing binding partner and an analyte specific moiety that comprises a second non-hybridizing binding partner, where the first and second binding partner comprises a binding pair;

(b) binding the analyte specific moiety to any analytes that may be

present in the specimen;

      (c) binding the composition to any bound analyte specific moieties from step (b) through interactions between the first binding partners and the second binding partners; and

      (d) measuring signal generation and thus detecting the presence or quantity of the analyte.

      The first and the second binding partners are paired members chosen from biotin/avidin, biotin/streptavidin, antigen/antibody, hormone/hormone receptor, lectin/sugar, enzyme/enzyme substrate, enzyme/substrate analog, enzyme/enzyme inhibitor, co-factor/co-factor enzyme binding site, and chelator/chelate. The analyte specific moiety comprises an antibody or an antigen. The method further involves providing one or more unlabeled nucleic acids. The unlabeled nucleic acid comprises some or all of the sequences of the nucleic acid portion in (Ic). (Ic) is also useful for detecting or quantifying an analyte in a specimen, which involves (a) providing a specimen where an analyte is sought to be detected or quantified, (Ic) comprising a first non-hybridizing binding partner a linking moiety comprising a second non-hybridizing binding partner and a third non-hybridizing binding partner, an analyte specific moiety that comprises a fourth non-hybridizing binding partner, where the first and the second binding partner comprise a first binding pair, and the third and the fourth binding partner comprises a second binding pair, performing or carrying out at least one binding reaction by binding the analyte specific moiety to any analytes that may be present in the specimen, binding the third binding partner to the fourth binding partner, binding the first binding partner to the second binding partner, to form a complex that comprises the analyte, the analyte specific moiety, the linking moiety and (Ic), and detecting or quantifying the amount of signal generation in the complex. The step of performing or carrying out the binding reactions is performed or carried out sequentially or concomitantly. In the providing step, the first binding pair and the second binding pair comprise the same pair of binding partners. The analyte specific moiety comprises an antibody or an antigen. (II) or (III) is useful for detecting or quantifying an analyte, which involves providing (II) or (III), where the target is an analyte specific moiety, contacting the (II) or (III) with a specimen suspected of containing the analyte, and measuring the amount of (II) or (III) bound to analytes in the specimen to detect or quantify the analyte (all claimed).

      ADVANTAGE - (I) detects or quantifies analyte with high sensitivity. In (I), the multiple labeled groups increases the amount of signal that is added to the analyte specific moiety, the presence of reactive groups enables attachment of the multiple labeled groups to a desirable target and the presence of charged group increases solubility.

```
L2    ANSWER 4 OF 8   USPATFULL on STN
AN      2003:237907   USPATFULL
TI      Compositions and methods for the therapy and diagnosis of colon cancer
IN      King, Gordon E., Shoreline, WA, UNITED STATES
        Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
        Xu, Jiangchun, Bellevue, WA, UNITED STATES
        Secrist, Heather, Seattle, WA, UNITED STATES
        Jiang, Yuqiu, Kent, WA, UNITED STATES
PA      Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI      US 20030166064     A1  20030904
AI      US 2002-99926      A1  20020314 (10)
RLI     Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,
        PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul
        2001, PENDING
PRAI    US 2001-302051P        20010629 (60)
        US 2001-279763P        20010328 (60)
```

```
          US 2000-223283P          20000803 (60)
DT     Utility
FS     APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
       SEATTLE, WA, 98104-7092
CLMN   Number of Claims: 17
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 8531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB   Compositions and methods for the therapy and diagnosis of cancer,
       particularly colon cancer, are disclosed. Illustrative compositions
       comprise one or more colon tumor polypeptides, immunogenic portions
       thereof, polynucleotides that encode such polypeptides, antigen
       presenting cell that expresses such polypeptides, and T cells that are
       specific for cells expressing such polypeptides. The disclosed
       compositions are useful, for example, in the diagnosis, prevention
       and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L2     ANSWER 5 OF 8   USPATFULL on STN
AN     2003:106233   USPATFULL
TI     Compositions and methods for the therapy and diagnosis of pancreatic
       cancer
IN     Benson, Darin R., Seattle, WA, UNITED STATES
       Kalos, Michael D., Seattle, WA, UNITED STATES
       Lodes, Michael J., Seattle, WA, UNITED STATES
       Persing, David H., Redmond, WA, UNITED STATES
       Hepler, William T., Seattle, WA, UNITED STATES
       Jiang, Yuqiu, Kent, WA, UNITED STATES
PA     Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI     US 20030073144     A1  20030417
AI     US 2002-60036      A1  20020130 (10)
PRAI   US 2001-333626P        20011127 (60)
       US 2001-305484P        20010712 (60)
       US 2001-265305P        20010130 (60)
       US 2001-267568P        20010209 (60)
       US 2001-313999P        20010820 (60)
       US 2001-291631P        20010516 (60)
       US 2001-287112P        20010428 (60)
       US 2001-278651P        20010321 (60)
       US 2001-265682P        20010131 (60)
DT     Utility
FS     APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
       SEATTLE, WA, 98104-7092
CLMN   Number of Claims: 17
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB   Compositions and methods for the therapy and diagnosis of cancer,
       particularly pancreatic cancer, are disclosed. Illustrative compositions
       comprise one or more pancreatic tumor polypeptides, immunogenic portions
       thereof, polynucleotides that encode such polypeptides, antigen
       presenting cell that expresses such polypeptides, and T cells that are
       specific for cells expressing such polypeptides. The disclosed
       compositions are useful, for example, in the diagnosis, prevention
       and/or treatment of diseases, particularly pancreatic cancer.

AN   2003:209861 USPATFULL
TI   HLA class I A2 tumor associated antigen peptides and vaccine
        compositions
IN   Fikes, John D., San Diego, CA, United States
        Sette, Alessandro, La Jolla, CA, United States
        Sidney, John, San Diego, CA, United States
        Southwood, Scott, Santee, CA, United States
        Celis, Esteban, Rochester, MN, United States
        Keogh, Elissa A., San Diego, CA, United States
        Chesnut, Robert, Cardiff-by-the-Sea, CA, United States
PA   Epimmune Inc., San Diego, CA, United States (U.S. corporation)
PI   US 6602510   B1 20030805
AI   US 2000-543608   20000405 (9)
DT   Utility
FS   GRANTED
EXNAM   Primary Examiner: Schwadron, Ronald B.
LREP   Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN   Number of Claims: 11
ECL   Exemplary Claim: 1
DRWN   5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 3397
AB   A composition or vaccine composition comprising eight isolated epitopes
        consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2),
        KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ.
        ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7),
        and, VVLGVVFGI (SEQ. ID. NO: 8).

AN   2002:272801 USPATFULL
TI   Compositions and methods for the therapy and diagnosis of colon cancer
IN   Stolk, John A., Bothell, WA, UNITED STATES
        Xu, Jiangchun, Bellevue, WA, UNITED STATES
        Chenault, Ruth A., Seattle, WA, UNITED STATES
        Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA   Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI   US 20020150922   A1 20021017
AI   US 2001-998598   A1 20011116 (9)
PRAI   US 2001-304037P   20010710 (60)
        US 2001-279670P   20010328 (60)
        US 2001-267011P   20010206 (60)
        US 2000-252222P   20001120 (60)
DT   Utility
FS   APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
        SEATTLE, WA, 98104-7092
CLMN   Number of Claims: 17
ECL   Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 9233
AB   Compositions and methods for the therapy and diagnosis of cancer,
        particularly colon cancer, are disclosed. Illustrative compositions
        comprise one or more colon tumor polypeptides, immunogenic portions
        thereof, polynucleotides that encode such polypeptides, antigen
        presenting cell that expresses such polypeptides, and T cells that are

specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 8 OF 8   USPATFULL on STN
AN   2002:243051   USPATFULL
TI   Compositions and methods for the therapy and diagnosis of ovarian cancer
IN   Algate, Paul A., Issaquah, WA, UNITED STATES
        Jones, Robert, Seattle, WA, UNITED STATES
        Harlocker, Susan L., Seattle, WA, UNITED STATES
PA   Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI   US 20020132237   A1 20020919
AI   US 2001-867701   A1 20010529 (9)
PRAI   US 2000-207484P   20000526 (60)
DT   Utility
FS   APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
        SEATTLE, WA, 98104-7092
CLMN   Number of Claims: 11
ECL   Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Compositions and methods for the therapy and diagnosis of cancer,
        particularly ovarian cancer, are disclosed. Illustrative compositions
        comprise one or more ovarian tumor polypeptides, immunogenic portions
        thereof, polynucleotides that encode such polypeptides, antigen
        presenting cell that expresses such polypeptides, and T cells that are
        specific for cells expressing such polypeptides. The disclosed
        compositions are useful, for example, in the diagnosis, prevention
        and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>